Intravenous Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia During Pregnancy: Effects on Maternal and Fetal Wellbeing—A Multicenter Retrospective Observational Study
Authors:
- Eleonora RomaniEREleonora Romani
- Sara ZullinoSZSara Zullino
- Anna R. SpecialeASAnna R. Speciale
- Paola M. VillaPVPaola M. Villa
- Veronica BonaldoVBVeronica Bonaldo
- Francesca ParisiFPFrancesca Parisi
- Chiara LubranoCLChiara Lubrano
- Felice PetragliaFPFelice Petraglia
- Irene CetinICIrene Cetin
- Federico MecacciFMFederico Mecacci
Open Access
Abstract
Objectives: To assess the impact of intravenous ferric carboxymaltose (FCM) on fetal and maternal adverse effects in pregnant women diagnosed with iron deficiency anemia (IDA). Methods: This is a multicenter retrospective study on 472 pregnant women diagnosed with moderate to severe IDA undergoing treatment with FCM between 2019 and 2025 at Careggi University Hospital (Florence) and Vittore Buzzi Children Hospital (Milan). Fetal wellbeing was assessed using computerized cardiotocography (cCTG) or ultrasound, based on gestational age at treatment. Maternal side effects were evaluated through clinical evaluation. Results: cCTG was performed in 377/472 patients (80%), with a mean short-term variability of 10.2 ms. Normal cCTG criteria were met in 98.4% of cases; six patients exhibited transient reduced variability, which resolved following intrauterine resuscitation. Ultrasound assessment was performed in 95 patients (20%), revealing no fetal heart rate abnormalities. Maternal side effects occurred in seven patients (1.4%). Hemoglobin concentrations increased by a median of 1.4 g/dL after five weeks, reaching up to 2.8 g/dL in women with a baseline Hb < 8 g/dL. Conclusions: Our findings support the potential safety and efficacy of intravenous FCM for the treatment of IDA during pregnancy, demonstrating low rates of maternal side effects and no adverse fetal heart rate patterns. However, prospective studies are necessary to confirm these results.Keywords
Funding Information
- University of Milan
- University of Florence
- Italian Ministry of Health
This publication has 26 references indexed in Scilit:
- Fetal bradycardia and acidosis during maternal parenteral iron: Case reports and literature reviewInternational Journal of Gynecology & Obstetrics, 2024
- Iron Deficiency and Iron Deficiency Anemia During Pregnancy—Opportunities to Optimize Perinatal Health and Health EquityJAMA Network Open, 2024
- Expert consensus guidelines: Intravenous iron uses, formulations, administration, and management of reactionsAmerican Journal of Hematology, 2024
- Overview of iron deficiency and iron deficiency anemia in women and girls of reproductive ageInternational Journal of Gynecology & Obstetrics, 2023
- The relationship between heavy menstrual bleeding, iron deficiency, and iron deficiency anemiaAmerican Journal of Obstetrics and Gynecology, 2023
- Intravenous ferric derisomaltose versus oral iron for persistent iron deficient pregnant women: a randomised controlled trialArchives of Gynecology and Obstetrics, 2022
- Iron Deficiency in Women’s Health: New Insights into Diagnosis and TreatmentAdvances in Therapy, 2022
- Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency AnemiaJAMA, 2020
- Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017Drug Safety, 2018
- Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancyArchives of Gynecology and Obstetrics, 2018